A carregar...
Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus
BACKGROUND: Since the approval of the first poly (adenosine diphosphate [ADP]) ribose polymerase inhibitor (PARPi; olaparib [Lynparza™]) for platinum-sensitive relapsed high grade ovarian cancer, with either germline or somatic BRCA1/2 deleterious variants, the strategies for BRCA1/2 are dynamically...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5929401/ https://ncbi.nlm.nih.gov/pubmed/29731958 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24728 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|